TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to ...

"These long-term results continue to support [pembrolizumab's] use as a standard of care for patients at increased risk of ...

Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the completion of enrollment in the Phase ...

Immunotherapy drug delays cancer recurring or worsening in global trial - A new study found the drug kept head and neck ...

A grandad diagnosed with stage 4 lung cancer–one of the deadliest—has become disease-free after being treated with an ...

Pembrolizumab with sacituzumab govitecan instead of chemotherapy led to improved progression-free survival in PD-L1-postive ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

A grandad with advanced lung cancer, which often leaves patients dead within four months has become free of the disease after ...

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...